RxDoctor Payments Data

Jonathan Eisengart, MD

Ophthalmology · South Euclid, OHNPI 1497748495

Payments from drug & device makers

$7,668in general payments, 2019–2025

Across 44 payments — averaging $174.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$3K
  • Alcon$1K
  • Nova Eye, Inc.$1K
  • AbbVie$730
  • Sight Sciences, Inc.$471
  • Aerie Pharmaceuticals, Inc.$391
  • plus $630 from 4 others

What the payments were for

  • Consulting fees$75010%
  • Speaking & faculty fees$1,50020%
  • Travel & lodging$1,17615%
  • Food & beverage$4,20255%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,668 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$233,519
Medicare patients
739
Services billed
2,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost324$160,574
RocklatanNetarsudil Mesylat/Latanoprost103$62,738
RhopressaNetarsudil Mesylate146$61,878
CombiganBrimonidine Tartrate/Timolol71$32,465
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,743$31,457
VyzultaLatanoprostene Bunod80$29,221
Brimonidine Tartrate1,043$26,690
Latanoprost1,876$25,396
Prednisolone Acetate560$25,360
RestasisCyclosporine23$25,277
SimbrinzaBrinzolamide/Brimonidine Tart67$20,700
Alphagan PBrimonidine Tartrate38$17,342
Bimatoprost126$14,765
Travoprost101$13,782
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$11,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$730$235,657456 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$391$124,616249 claims
Bausch & Lomb Americas Inc.Vyzulta$22$29,22180 claims
AlconSimbrinza$1,353$20,70067 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$64$3,66817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in South Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →